Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Franklin Biotechnology Discovery Fund Class A (FBDIX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
Sales Expenses
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.


1 month+7.29% 3 years+1.96%
3 months+3.66% 5 years+18.16%
1 year+22.11% Since inception+11.58%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+18.16%+17.28%
Expense ratio1.06%1.32%
Risk 5 year sharpe ratio0.811.11
Net assets$1.4B$3.0B
Average market cap$10.1B$9.3B
Average P/E--21.8
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$1,000.00
Minimum IRA investment$250.00


U.S. stock94.96%
International stock2.42%
Fixed income0.43%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
CELG Celgene10.02%
ALXN Alexion Pharmaceuticals Inc8.02%
INCY Incyte Corp5.01%
BIIB Biogen4.86%
REGN Regeneron Pharmaceuticals4.67%
GILD Gilead Sciences4.54%
ILMN Illumina Inc4.19%
VRTX Vertex Pharmaceuticals Inc4.00%
NBIX Neurocrine Biosciences Inc3.61%
CLVS Clovis Oncology Inc3.48%